Vivo Bio Tech (VIVOBIOT) is loss-making over the last 12 months, losing ₹2.86 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹14.65, 28% below its 52-week high. Sales grew 0.7% a year over 3 years. Debt is 0.72× equity. It is a small-cap company with a market cap of ₹33 Cr, ranked 16th of 20 Biotechnology companies by market cap; the shares fell 23% over the past year.
- ₹14.94
- ₹15.06
- ₹14.11
- ₹14.76
- 10K
Health check
- ReturnsBehind
−22.7% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +0.7% a year over 3 years, but loss-making now.
- ProfitabilityWeak
ROCE 7.2% vs peer median 16.7%.
- Balance sheetStretched
Debt 0.72× equity, interest covered 1.8×, Piotroski 2 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹33 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 0.32
- Peers 4.68
- Dividend yield
- 0.00%
- ROE
- −2.0%
- Peers 14.3%
- ROCE
- 7.2%
- Peers 16.7%
- Debt to equity
- 0.72
- Debt ₹67 Cr
- EPS (TTM)
- −₹1.43
- Face value ₹10
- OPM (TTM)
- 38.1%
- Net margin −5.2%
- Sales growth
- +14.1%
- Latest quarter vs a year ago
- Profit growth
- −86.0%
- Latest quarter vs a year ago
- Price to sales
- 0.59
- EV/EBITDA 4.8
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −2.0%.
- Quarterly profit down 86.0% on a year ago.
About Vivo Bio Tech
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, analytical, and other services. It also supplies specific pathogen free lab animals; breeders and distributes rodent models; and designs and develops of…
- Headquarters
- Hyderabad
- Employees
- 247
- Sector
- Healthcare
- ISIN
- INE380K01017
- Website
- vivobio.com
Price range
- Avg volume (3M)
- 28.7K
- 1-year return
- minus 22.7%
- From 52-week high
- minus 28.3%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 20.5% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.56% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.21% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.11% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| VIVOBIOTVivo Bio Tech | 14.65 | minus 0.75% | 33 | – | 0.32 | 7.2% | −2.0% | 38.1% | 0.7% | – | 0.00% | minus 22.7% |
| Median of 7 peers | – | 0.22% | 13,236 | 47.4 | 4.68 | 16.7% | 14.3% | 23.5% | 21.2% | 15.4% | 0.14% | −5.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 12.5 | 13.1 | 13.5 | 14.2 | 14.3 | |
| 7 | 7.7 | 8 | 9.1 | 9.2 | |
| 5.5 | 5.4 | 5.5 | 5.1 | 5.1 | |
| 43.9% | 41.3% | 40.7% | 35.6% | 35.4% | |
| 0.1 | 0.1 | 0.1 | 0 | 0.1 | |
| 1.5 | 1.5 | 1.4 | 1.5 | 1.2 | |
| 2.6 | 2.6 | 2.7 | 2.8 | 3.5 | |
| – | – | – | −0.6 | – | |
| 1.5 | 1.5 | 1.6 | 0.3 | 0.3 | |
| 9.7% | 42.4% | 20.5% | 2156.0% | 44.6% | |
| 1.3 | 0.9 | 1.2 | −5.2 | 0.2 | |
| 0.74 | 0.45 | 0.56 | -2.52 | 0.08 |
Profit & loss
- Sales CAGR 3Y
- +0.7%
- ROE
- −2.0%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 52.2 | 45.5 | 46.7 | 53.3 | |
| – | minus 13.0% | +2.7% | +14.3% | |
| 30.4 | 24.2 | 26.1 | 31.8 | |
| 21.8 | 21.3 | 20.6 | 21.5 | |
| 41.8% | 46.8% | 44.0% | 40.3% | |
| −0.3 | −0.2 | 0.1 | 0.4 | |
| 7.7 | 7.8 | 7.5 | 5.8 | |
| 9.3 | 9.3 | 9 | 10.6 | |
| – | – | 4.6 | −0.6 | |
| 4.6 | 4.1 | 8.8 | 4.8 | |
| 42.7% | 37.8% | 17.2% | 135.5% | |
| 2.6 | 2.5 | 7.3 | −1.7 | |
| – | minus 4.6% | +188.3% | minus 123.5% | |
| 1.78 | 1.51 | 4.76 | -0.82 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 14.9 | 14.9 | 17.2 | 22.2 | |
| 37 | 39.5 | 60.7 | 71 | |
| 62.4 | 73.1 | 54 | 67.4 | |
| 8.8 | 9.7 | 11.3 | 17.9 | |
| 123 | 137 | 143 | 178 | |
| 80 | 81.4 | 77.1 | 76.2 | |
| 1.9 | 9.2 | 12.8 | 4.8 | |
| – | – | – | 21.9 | |
| 1.4 | 1.4 | 1.3 | 1.4 | |
| 39.8 | 45.2 | 52 | 74.1 | |
| 123 | 137 | 143 | 178 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 14.8 | 15.5 | 11.8 | 34.9 | |
| −4 | −8 | −15.8 | −59.3 | |
| −11.2 | −7.6 | 3.9 | 24.6 | |
| −0.3 | 0 | −0.1 | 0.2 | |
| −4 | −8 | −22.3 | −37.4 | |
| 10.8 | 7.6 | −10.4 | −2.5 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company.
Major shareholders
Filings & events
News
No recent news coverage found.